Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer.

Trial Profile

Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2010

At a glance

  • Drugs Exemestane; Sunitinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jun 2009 Results were presented at ASCO 2009.
    • 20 May 2009 Planned end date changed from 1 Oct 2011 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top